Q-omics provides the consensus-scored MARCHF5 profile across patient tissues and cancer cell-line models. MARCHF5 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, MARCHF5 is differentially expressed in 14, with the highest sampling consensus in KIRC. Additionally, MARCHF5 RNA expression shows 19,759 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight ACC, and KIRC as cancer lineages where MARCHF5 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MARCHF5 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MARCHF5 survival associations across molecular data types. MARCHF5 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (6) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MARCHF5 RNA expression–survival associations across cancer types. High MARCHF5 expression shows unfavorable associations in ACC, HNSC and SARC, but favorable associations in KIRC, LGG and UCS. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for MARCHF5 RNA expression.
This table summarizes MARCHF5 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14, while mass-spec protein shows differences in 4. The strongest signals are observed in LIHC for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for MARCHF5. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MARCHF5 shows lower tumor expression in KIRC and KICH and higher tumor expression in LIHC, LUAD, BLCA and UCEC. The KIRC box plot shows higher MARCHF5 RNA expression in normal versus tumor tissue (log2 FC = −0.637, t-test p < 0.001).
This table shows molecular features associated with MARCHF5 in patient tissues and cancer cell lines. In patient samples, MARCHF5 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, MARCHF5 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Leukemia, while CRISPR and shRNA rows add functional-dependency signals in LUNG_SCLC and BONE.
